Get the Stockscreener App
12.75
50.18%
4.26
Pre-market:
11.03
-1.72
-13.49%
Polyrizon Ltd stock is traded at $12.75, with a volume of 1.15M.
It is up +50.18% in the last 24 hours and up +73.94% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$8.49
Open:
$8.23
24h Volume:
1.15M
Relative Volume:
0.40
Market Cap:
$13.28M
Revenue:
-
Net Income/Loss:
$-1.13M
P/E Ratio:
-0.223
EPS:
-57.1626
Net Cash Flow:
$-2.63M
1W Performance:
+56.63%
1M Performance:
+73.94%
6M Performance:
+195.14%
1Y Performance:
-99.54%
1-Day Range:
$8.23
$14.45
1-Week Range:
$7.561
$14.45
52-Week Range:
$2.88
$3,000.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
12.75 | 8.84M | 0 | -1.13M | -2.63M | -57.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon submits pre-request to FDA for nasal spray against flu - Investing.com Nigeria
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Polyrizon submits pre-request to FDA for nasal spray against flu By Investing.com - Investing.com South Africa
Polyrizon stock rises on FDA submission for PL-16 viral blocker - Investing.com
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated - The Manila Times
Could a simple nasal spray add a drug-free layer of flu protection? - Stock Titan
Polyrizon (PLRZ) Stock Analysis Report | Financials & Insights - Benzinga
Polyrizon reports mucoadhesion results for intranasal naloxone hydrogel - MSN
Polyrizon to explore investments in revenue-generating assets By Investing.com - Investing.com Nigeria
Polyrizon to pursue revenue-generating real assets while advancing intranasal biotech pipeline - MSN
Polyrizon stock rises as company explores revenue-generating investments By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon to explore investment in revenue-generating real assets - marketscreener.com
Polyrizon to Pursue Revenue-Generating Real Assets While Advancing Intranasal Biotech Pipeline - TipRanks
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet - The Manila Times
Biotech with no debt looks beyond the lab to buy real assets - Stock Titan
Polyrizon completes manufacturing upscaling milestone for nasal spray platform - MSN
Top Medical Stocks To Keep An Eye OnDecember 2nd - MarketBeat
What risks investors should watch in Polyrizon Ltd. stockPortfolio Performance Report & Fast Gain Stock Trading Tips - moha.gov.vn
Biotech alert: Searches spiking for these stocks today - MSN
Polyrizon completes FDA pre-submission meeting for PL-14 nasal spray - MSN
Polyrizon unveils promising results for intranasal naloxone hydrogel - MSN
Aug Drivers: What risks investors should watch in Polyrizon Ltd. stock2025 Growth vs Value & Capital Protection Trade Alerts - Улправда
Polyrizon submits pre-request for designation to FDA for PL-16 viral blocker - marketscreener.com
Polyrizon Files FDA Pre-Request for Designation of PL-16 Intranasal Viral Blocker - TipRanks
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses - The Manila Times
Pre-clinical nasal ‘viral blocker’ aims to cut flu and cold exposure - Stock Titan
Is Polyrizon Ltd. stock undervalued vs historical averagesEarnings Growth Summary & Real-Time Market Sentiment Alerts - bolumsonucanavari.com
Winners Losers: Can Polyrizon Ltd stock attract ESG capital inflows2025 AllTime Highs & Breakout Confirmation Trade Signals - moha.gov.vn
Resistance Check: Is Polyrizon Ltd stock a buy on dipsShort Setup & Safe Entry Point Identification - moha.gov.vn
Polyrizon’s naloxone hydrogel shows positive permeation kinetics - TipRanks
Polyrizon’s intranasal naloxone hydrogel shows promising test results - Investing.com
Polyrizon Unveils Promising Results for Intranasal Naloxone Hydrogel - TipRanks
Polyrizon’s intranasal naloxone hydrogel shows promising test results By Investing.com - Investing.com Canada
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program - The Manila Times
[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal ... - Enidnews.com
Polyrizon (Nasdaq: PLRZ) shows rapid permeation in intranasal naloxone hydrogel preclinical studies - Stock Titan
Polyrizon Ltd trading halted, news pending - MSN
Earnings Update: Is Polyrizon Ltd stock a buy on dipsJuly 2025 Action & Real-Time Stock Price Movement Reports - BỘ NỘI VỤ
Polyrizon completes FDA pre-submission meeting for allergy blocker - Investing.com
Polyrizon Advances PL-14 Nasal Spray with FDA Meeting - TipRanks
Polyrizon completes FDA pre-submission meeting for allergy blocker By Investing.com - Investing.com India
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray - The Manila Times
Polyrizon completes FDA pre-submission meeting for PL-14 allergy blocker nasal spray - marketscreener.com
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray - GlobeNewswire Inc.
Top Biotech Stocks To ConsiderDecember 4th - MarketBeat
Small Cap Stocks To Keep An Eye OnDecember 4th - MarketBeat
Top Biotech Stocks To Consider – December 4th - Defense World
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):